We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
-0.84%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$5.11M
Cap. Flow
+$8.26M
Cap. Flow %
3.42%
Top 10 Hldgs %
57.4%
Holding
86
New
15
Increased
42
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$7.21M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.91M
3
VCYT icon
Veracyte
VCYT
+$5.84M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.65M
5
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$3.13M

Top Sells

Rank Stock Value
1
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.42M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.38M
3
IMGN
Immunogen Inc
IMGN
+$4.81M
4
HALO icon
Halozyme
HALO
+$2.85M
5
CYTK icon
Cytokinetics
CYTK
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 85.52%
2 Miscellaneous 12.62%
3 Financials 1.28%
4 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
1
LeonaBio Inc
LONA
$74.8M
$27M 11.16%
+1,000
New +$105K
XBI icon
2
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$27M 11.16%
300,000
+100,000
+50% +$9.23M
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.9M 7.82%
308,819
+113,819
+58% +$5.91M
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$14.2M 5.88%
443,381
+251,336
+131% +$7.21M
VCYT icon
5
Veracyte
VCYT
$3.48B
$11.7M 4.86%
425,554
+204,192
+92% +$5.84M
CTIC
6
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$10.5M 4.35%
2,250,000
+766,171
+52% +$2.29M
MRUS
7
DELISTED
Merus
MRUS
$8.59M 3.55%
324,719
+4,545
+1% +$122K
CERS icon
8
Cerus
CERS
$534M
$7.68M 3.18%
1,398,400
+355,678
+34% +$1.97M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$7.1M 2.94%
67,442
+5,742
+9% +$560K
APEN
10
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.08M 2.51%
1,004,399
+264,795
+36% +$1.61M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$5.35M 2.22%
+105,368
New +$4.65M
ACRS icon
12
Aclaris Therapeutics
ACRS
$885M
$4.75M 1.96%
275,333
-10,893
-4% -$149K
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
$4.47M 1.85%
138,843
+837
+0.6% +$30.4K
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.36M 1.8%
102,497
+22,149
+28% +$2.76M
COGT icon
15
Cogent Biosciences
COGT
$6.02B
$4.3M 1.78%
573,699
-277,236
-33% -$1.93M
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.79M 1.57%
46,122
-14,635
-24% -$1.5M
IMTX icon
17
Immatics
IMTX
$1.44B
$3.56M 1.47%
445,334
+54,179
+14% +$494K
KRYS icon
18
Krystal Biotech
KRYS
$10.4B
$3.09M 1.28%
46,489
-181
-0.4% -$11.3K
IMGN
19
DELISTED
Immunogen Inc
IMGN
$3.07M 1.27%
645,000
-869,411
-57% -$4.81M
NGM
20
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.06M 1.27%
+200,494
New +$3.13M
OTIC
21
DELISTED
Otonomy, Inc.
OTIC
$2.9M 1.2%
1,207,385
+7,571
+0.6% +$16.1K
MORF
22
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.76M 1.14%
68,709
+1,269
+2% +$53.1K
UTHR icon
23
United Therapeutics
UTHR
$22.1B
$2.66M 1.1%
14,836
+285
+2% +$54.3K
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$2.54M 1.05%
41,002
-87,899
-68% -$5.38M
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$9B
$2.5M 1.04%
114,004
+2,144
+2% +$43.4K
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Silverarc Capital Management held 86 positions worth $242M, down 2.1% from $247M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Silverarc Capital Management deployed $8.26M of net new capital in Q1 2022, opening 15 new positions and adding to 42 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 105,368 shares worth $5.35M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.38M trimmed.

  • Silverarc Capital Management's largest Q1 2022 buy was Apellis Pharmaceuticals: 105,368 shares worth $5.35M.
  • Silverarc Capital Management added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $7.21M increase.
  • Silverarc Capital Management's biggest Q1 2022 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.38M.
  • Silverarc Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $5.42M.
  • Silverarc Capital Management's ten largest holdings make up 57% of its $242M portfolio in Q1 2022.
  • Silverarc Capital Management opened 15 new positions and closed 17 in Q1 2022.
  • Silverarc Capital Management's portfolio value fell 2.1% quarter-over-quarter to $242M.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.